US Stock MarketDetailed Quotes

CYBN Cybin

  • 0.3577
  • -0.0100-2.72%
Trading Apr 22 14:48 ET
271.75MMarket Cap-1640P/E (TTM)

About Cybin Company

Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Company Profile

Company NameCybin
Listing DateAug 5, 2021
CEOMr. Douglas Drysdale
Securities TypeOrdinary Shares
Fiscal Year Ends03-31
Address100 King Street West,Suite 5600
Zip CodeM5X 1C9

Company Executives

  • Name
  • Position
  • Salary
  • Douglas Drysdale
  • Chief Executive Officer
  • 834.17K
  • Alex Nivorozhkin
  • Chief Scientific Officer
  • --
  • Paul Glavine
  • Director and Chief Growth Officer
  • 624.00K
  • Greg Cavers
  • Chief Financial Officer
  • 329.20K
  • Gabriel Fahel
  • Chief Legal Officer and Corporate Secretary
  • --
  • Eric So
  • Director and President
  • 624.00K
  • Mark Lawson
  • Independent Director
  • 50.00K
  • Grant Froese
  • Independent Director
  • 50.00K
  • Dr. Eric Hoskins
  • Independent Director
  • 50.00K
  • Theresa Firestone
  • Lead Independent Director
  • 65.00K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price